Conclusion: BVS absorb Everolimus eluting vascular scaffold showed favorable clinical outcome without any major cardiac events (acute or late stent thrombosis, MI or death) over a period of 9 month. Thus, BVS absorb would be favorable alternative to other available drug eluting metallic stents.
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Two-year Clinical Outcomes of Patients with Drug Eluting Stents in Diffuse Long Lesions; Comparison of 1st Generation Sirolimus Eluting Stent Versus 2nd Generation Everolimus Eluting Stent
Jeong-Hwan Cho 1 , Chan-Hee Lee 1 , Hyun-Wook Lee 1 , Tae-Hun Kwon 1 , Yoon-Jung Choi 1 , Jang-Won Son 1 , Sang-Hee Lee 1 , Ung Kim 1 , Jeon-Seon Park 1 , Dong-Gu Shin 1 , Young-Jo Kim 1 , Han-Young Jin 2 , Jae-Sik Jang 2 , Tae-Hyun Yang 2 , Doo-Il Kim 3 , Pil-Sang Song 3 , Sang-Hoon Seol 3 , Kwon-Bae Kim 4 , Seung-Ho Hur 4 , Hyuck-Jun Background: The aim of this study is to compare clinical outcomes between 1 st generation sirolimus eluting stent and 2 nd generation everolimus eluting stent in patients with diffuse long lesions for 2 years. Methods: A total 381 Patients with diffuse long lesion treated with ! 50 mm stent segment in de novo lesions from Jan 2006 to Aug 2011 were enrolled. The patients were divided into two groups as sirolimus eluting stent (SES, n¼265) group and everolimus eluting stent (EES, n¼116) group. Study end-points were major adverse cardiac events (MACE) including all death, myocardial infarction (MI), and ischemic driven target vessel revascularization (Id-TVR). Results: Baseline characteristics were similar. Stent length was 61.7AE11.0 in SES and 62.8AE13.7 in EES (p¼0.593). For 2 years clinical follow-up, the rate of cumulative MACE was 10.7% in SES and 7.4% in EES (p¼0.346) . The rate of all death was observed 5.7% in SES and 6.3% in EES group (p¼0.840). The rate of MI was observed 2.3% in SES and 5.3% in EES (p¼0.153). The rate of Id-TVR was observed 7.7% in SES and 6.3% in EES (p¼0.666). Conclusion: The clinical outcomes between SES and EES in patients with diffuse long lesions were not different for 2 years. Further longer term follow-up and larger population study will be needed for better evaluation. Key word: Sirolimus-Eluting stent, Everolimus-Eluting stent, Diffuse long lesion. Background: Previous studies have demonstrated that patients with small coronary artery lesions (SCAL) are at increased risk for late cardiac events after percutaneous coronary intervention (PCI). It remains uncertain whether second-generation drugeluting stents have an advantage first-generation drug-eluting stents (DES) in patients with SCAL. This study aimed to evaluate the long-term efficacy of everolimus-eluting stent(EES) and sirolimus-eluting stents(SES) on SCAL. Methods: Consecutive 353 patients with 400 SCAL, who were treated with EES (153 patients, 180 lesions) and SES (203 patients, 220 lesions) were enrolled. SCAL was defined the lesions with reference vessel diameter(RVD) <2.5 mm. Within ten months angiographic follow-up results and 2-year clinical follow-up outcomes were compared between EES and SES groups. Results: The prevalence of diabetes was higher and the stent length was longer (22.9AE7.0 vs. 20.1AE7.0, p<0.05) in EES group than in SES group. Initial success rate was similar in both groups. There was no difference in 2-year %binary restenosis, TLR (1.7vs. 4.7%), and MACE (3.3%vs 6.4%) rates between 2 groups. This similar major adverse cardiovascular events rate remained after adjustment. However, the rate of stent thrombosis was 0% in the EES group and 1.8% in the SES group (p ¼ 0.12). Conclusion: EES demonstrated comparable clinical outcomes to those of SES in SCAL. The absence of stent thrombosis among patients treated with EESs suggests a good safety profile for this second-generation drug-eluting stent, which should be carefully studied in a larger series of patients with SCAL. Background: Nature of Coronary artery disease (CAD) in Bangladeshi population is diffuse with small caliber arteries. Now a days, these are treated, by PCI with stent deployment. However, long term data on In-stent re-stenosis (ISR) in these patients are not yet available. Therefore, the aim of our present study was to assess long-term outcome of stent patency or the development of ISR of varieties stent in single vessel territory. Methods: Patients were selected retrospectively, who underwent coronary angiogram at our hospital for further evaluation of their previous PTCA in the 3->36 months preceding the study for the quantifying period of 2006 -2012 were included in this study. Average age was Male: 56; Female: 59. Average study period was 3.4. Results: Our result shows that among the total studied population 82.1% (474) were male and 17.9% (103) were female. Female were more obese than male BMI (27 vs 26). Total 864 stent were deployed in 785 vessels. 
